BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT).

The kinetics and predictive value of HIV-1 DNA (HIV DNA) levels in relapsed or refractory HIV lymphoma patients, treated with high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT), were investigated.

HIV DNA was measured by real-time PCR in the peripheral blood mononuclear cells (PBMCs) of 22 patients observed for a median follow-up of 31.0 months.

At baseline, HIV DNA was found to be correlated with HIV-1 RNA (HIV RNA) (r = 0.56), but not with CD4(+) counts (r = -0.10).

HIV RNA load was under control for the entire follow-up, while HIV DNA levels were almost always detectable (baseline levels vs. 1 year from ASCT levels, p > 0.05).

Baseline HIV DNA levels were significantly different between alive and deceased patients (p = 0.03), and the overall survival (OS) analysis showed that for patients with higher HIV DNA levels at baseline there was a higher and nearly significant risk of death if compared to patients with lower levels (HR, 8.33, 95% CI, 0.99-70.06, p = 0.05).

Our study demonstrated that high HIV DNA levels at baseline could predict overall survival after ASCT in one of the largest cohorts of HIV lymphoma patients treated with salvage therapy.

[MeSH-major] Antineoplastic Agents / therapeutic use. DNA, Viral / blood. HIV-1 / isolation & purification. Lymphoma, AIDS-Related / mortality. Stem Cell Transplantation. Viral Load

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20156109.001).

[ISSN] 1931-8405

[Journal-full-title] AIDS research and human retroviruses

[ISO-abbreviation] AIDS Res. Hum. Retroviruses

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Virus-associated lymphomagenesis.

Lymphomas are one of the best studied cancer types closely associated with a small but definite range of viruses.

Numerous data show a close interrelation between lymphomagenesis and infection by such viruses as Kaposi's sarcoma herpesvirus (KSHV), Epstein-Barr virus (EBV), hepatitis C virus (HCV), human T-cell leukemia virus (HTLV), and human immunodeficiency virus (HIV).

For instance, experiments on monkeys artificially infected with viruses and data on anti-cancer effect of specific antiviral preparations strongly suggest the involvement of viruses in lymphoma development.

The present review is devoted to the association of different viruses with human lymphomas and to viral genes potentially involved in the neoplastic process.

The recognition of virus involvement in lymphomagenesis may facilitate new strategies for cancer therapy, diagnosis and screening and can lead to a reduction in the number of individuals at risk of disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 23674972.001).

[ISSN] 1550-9702

[Journal-full-title] International journal of biomedical science : IJBS

[ISO-abbreviation] Int J Biomed Sci

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC3614592

[Keywords] NOTNLM ; HIV / HIV virus HIV / epstein-barr virus / epstein-barrvirus / hepatitis b virus / hepatitis cvirus / herpesvirus / lymphoma / oncogenicity / virus

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Plasmablastic lymphoma: a clinicopathologic correlation.

Plasmablastic lymphoma (PBL) is an uncommon, recently described B-cell-derived lymphoma that displays distinctive affinity for extranodal presentation in the oral cavity.

Plasmablastic lymphoma is strongly associated with human immunodeficiency virus (HIV) infection, but has been reported in HIV-negative individuals.

Plasmablastic lymphoma may be poorly recognized by pathologists, which is partly attributable to its relatively rare occurrence and unusual immunophenotype.

Five cases of oral cavity lymphomas conforming to the current World Health Organization morphological criteria for PBL were retrieved from the consultation files at the Armed Forces Institute of Pathology.

Follow-up revealed only 1 patient alive with no evidence of disease.

Our cases show that PBL is an aggressive type of B-cell lymphoma predominantly found in the oral cavity.

Plasmablastic lymphoma is often associated with HIV infection.

[MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Mouth / pathology. Mouth Neoplasms / pathology. Plasma Cells / pathology

MedlinePlus Health Information. consumer health - Oral Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16414538.001).

[ISSN] 1092-9134

[Journal-full-title] Annals of diagnostic pathology

[ISO-abbreviation] Ann Diagn Pathol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; EC 3.2.2.5 / Antigens, CD38

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status.

Plasmablastic lymphoma (PBL) is a rare acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma (AIDS-NHL), with predilection for the mucosa of oral cavity.

It usually has a plasmablastic morphology, expressing plasma cell-associated antigens with weak or absent expression of B-cell-associated markers.

To further define the immunophenotypic and molecular genetics of these tumors, we investigated two cases of plasmablastic lymphomas of the head and neck for c-myc gene rearrangement and immunoglobulin heavy chain (IgV(H)) hypermutation status.

For the first time we report a case of AIDS-related PBL that, by fluorescence in situ hybridization (FISH), shows a c-myc gene rearrangement.

Although current literature suggests that most cases of c-myc gene rearranged AIDS-NHL are Burkitt's lymphoma, our case has an immunophenotype characteristic for PBL.

The concurrent B-cell immunophenotype of BCL-6(-)/CD138(+)/MUM-1(+) also suggests a post-germinal center B-cell origin of this lymphoma.

[MeSH-major] Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Mouth Neoplasms / pathology. Proto-Oncogene Proteins c-myc / genetics

MedlinePlus Health Information. consumer health - Oral Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leuk Lymphoma. 2005 Jan;46(1):77-81 [15621784.001]

[Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]

[Cites] Cancer. 2005 Jun 25;105(3):139-44 [15803491.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):198-206 [16037778.001]

[Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]

[Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]

[Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]

[Cites] Hum Pathol. 2002 Apr;33(4):392-404 [12055673.001]

[Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]

[Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]

[Cites] J Clin Oncol. 2003 Nov 1;21(21):3928-32 [14581416.001]

[Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]

[Cites] J Natl Cancer Inst Monogr. 1998;(23):95-100 [9709310.001]

[Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]

[Cites] Blood. 1993 Jan 1;81(1):166-76 [8380252.001]

[Cites] Blood. 1993 Jul 15;82(2):552-63 [8392399.001]

[Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]

[Cites] Semin Diagn Pathol. 1997 Feb;14(1):67-82 [9044511.001]

(PMID = 20614267.001).

[ISSN] 1936-0568

[Journal-full-title] Head and neck pathology

[ISO-abbreviation] Head Neck Pathol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc

[Other-IDs] NLM/ PMC2807524

[Keywords] NOTNLM ; Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma / Immunoglobulin variable heavy chain hypermutation status / Plasmablastic lymphoma / c-myc gene rearrangement

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: Sub-Saharan Africa has the highest number of HIV/AIDS cases globally which contrasts with the lack of population-based studies of oral Kaposi's sarcoma (OKS); one of the clinical cardinal signs of HIV/AIDS.

To date, no study has investigated the incidence of OKS in African populations affected by the HIV/AIDS epidemic.

Among AIDS-associated malignancies, OKS accounted for 98% while the balance comprised Burkitt's lymphoma, Hodgkin's and Non-Hodgkin's lymphomas, haemangiosarcoma and lymphoma not specified.

These findings are attributable to the high human immunodeficiency virus infection (HIV) rates recorded for

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

MedlinePlus Health Information. consumer health - Oral Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21644423.001).

[ISSN] 0008-9176

[Journal-full-title] The Central African journal of medicine

[ISO-abbreviation] Cent Afr J Med

[Language] eng

[Publication-type] Journal Article

[Publication-country] Zimbabwe

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma.

We report an HIV-positive patient who developed a unilateral retinitis and subsequent intracranial lesions.

The finding of Epstein Barr virus (EBV) DNA at a > 1-log greater concentration in the vitreous compared to blood raised the possibility of a primary CNS non-Hodgkin's lymphoma, which was subsequently confirmed on brain biopsy.

[MeSH-major] DNA, Viral / genetics. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16321894.001).

[ISSN] 0927-3948

[Journal-full-title] Ocular immunology and inflammation

[ISO-abbreviation] Ocul. Immunol. Inflamm.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / DNA, Viral

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Control of human herpes virus type 8-associated diseases by NK cells.

NK cell activity is reduced during disease progression in human immunodeficiency virus (HIV) infection, and in individuals with AIDS-associated tumors linked with infection by the oncogenic human herpes virus type-8 (HHV8), including Kaposi's sarcoma (KS) and primary effusion lymphomas (PEL).

We have demonstrated that AIDS-related KS (AIDS-KS) is characterized by an increased expression of inhibitory receptors by T lymphocytes, and that HIV-non-infected patients with KS (classic KS, C-KS) have a substantial number of NK cells bearing these same receptors.

However, the cytotoxic activity of NK cells is reduced in patients with C-KS, AIDS-KS, or PEL patients, who are all infected by the HHV8, and this correlates with disease severity.

Since PEL cells express the same HHV8 latency program as KS cells, these data point to MHC-I downregulation by HHV8 as a primary immune evasion mechanism against CTL responses, further reinforced by upregulation of inhibitory receptors on T and NK cells in the setting of HIV and/or HHV8 infection.

Thus, studies on killing receptor regulation and signaling in T and NK cells may shed light on the pathogenesis of HHV8-associated tumors both in HIV-infected or -noninfected patients.

[MeSH-minor] Cytotoxicity, Immunologic. HIV Infections / complications. HIV Infections / therapy. Histocompatibility Antigens Class I / metabolism. Humans. Immune System. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / virology. Signal Transduction. T-Lymphocytes / metabolism. T-Lymphocytes, Cytotoxic / metabolism

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17405914.001).

[ISSN] 0077-8923

[Journal-full-title] Annals of the New York Academy of Sciences

[ISO-abbreviation] Ann. N. Y. Acad. Sci.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Histocompatibility Antigens Class I

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

LCL formation serves as a model for lymphomagenesis, and LCLs are phenotypically similar to EBV-positive diffuse large B-cell lymphomas (DLBCLs), which represent a common AIDS-associated malignancy.

B-cell infection by EBV induces the expression of several cellular microRNAs (miRNAs), most notably miR-155, which is overexpressed in many tumors and can induce B-cell lymphomas when overexpressed in animals.

In contrast, three other B-cell lymphoma lines, including two EBV-positive Burkitt's lymphoma cell lines, grew normally in the absence of miR-155 function.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Virol. 2006 Jun;80(11):5321-6 [16699012.001]

[Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]

[Cites] J Gen Virol. 2006 Oct;87(Pt 10):2885-90 [16963746.001]

[Cites] Science. 2007 Apr 27;316(5824):604-8 [17463289.001]

[Cites] Science. 2007 Apr 27;316(5824):608-11 [17463290.001]

[Cites] Nucleic Acids Res. 2007;35(10):e73 [17478510.001]

[Cites] Int J Cancer. 2007 Sep 1;121(5):1156-61 [17487835.001]

[Cites] Nat Methods. 2007 Sep;4(9):721-6 [17694064.001]

[Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]

[Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]

[Cites] Immunity. 2007 Dec;27(6):847-59 [18055230.001]

[Cites] Cancer Genet Cytogenet. 2008 Feb;181(1):8-15 [18262046.001]

[Cites] J Pathol. 2008 May;215(1):13-20 [18348159.001]

[Cites] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323.001]

[Cites] Nat Biotechnol. 2008 Apr;26(4):407-15 [18392026.001]

[Cites] J Virol. 2008 Jun;82(11):5295-306 [18367535.001]

[Cites] Immunity. 2008 May;28(5):621-9 [18450484.001]

[Cites] Immunity. 2008 May;28(5):630-8 [18455451.001]

[Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]

[Cites] Nature. 2008 Aug 7;454(7205):780-3 [18596690.001]

[Cites] Cancer Res. 2008 Oct 1;68(19):8164-72 [18829576.001]

[Cites] J Virol. 2008 Nov;82(21):10436-43 [18753206.001]

[Cites] Biochem Biophys Res Commun. 2008 Dec 12;377(2):579-83 [18926796.001]

[Cites] Nucleic Acids Res. 2008 Nov;36(20):6608-19 [18940871.001]

[Cites] J Virol. 2008 Dec;82(24):12213-20 [18842708.001]

[Cites] Virology. 2008 Dec 20;382(2):257-66 [18950829.001]

[Cites] J Virol. 2009 Jan;83(1):489-92 [18945769.001]

[Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]

[Cites] J Virol. 2009 Apr;83(7):3333-41 [19144710.001]

[Cites] Leukemia. 2009 Apr;23(4):807-10 [18987659.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7113-8 [19359473.001]

[Cites] Genes Dev. 2009 May 15;23(10):1151-64 [19451215.001]

[Cites] J Virol. 2009 Dec;83(23):12009-17 [19759154.001]

[Cites] RNA Biol. 2009 Nov-Dec;6(5):541-5 [19901530.001]

[Cites] J Virol. 2010 Jan;84(2):695-703 [19889781.001]

[Cites] EMBO Mol Med. 2009 Aug;1(5):288-95 [19890474.001]

[Cites] Science. 2010 Jan 8;327(5962):198-201 [19965718.001]

[Cites] Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3111-6 [20133617.001]

[Cites] Cell. 2010 Apr 2;141(1):129-41 [20371350.001]

[Cites] J Virol. 2010 May;84(10):5229-37 [20219912.001]

[Cites] J Virol. 2010 Jul;84(13):6318-27 [20427544.001]

[Cites] Mol Cell. 2002 Jun;9(6):1327-33 [12086629.001]

[Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]

[Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]

[Cites] Nature. 1988 Sep 8;335(6186):181-3 [3412474.001]

[Cites] Mol Cell Biol. 1989 Jun;9(6):2657-64 [2548084.001]

[Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]

[Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]

[Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):103-6 [16175574.001]

[Cites] Genes Chromosomes Cancer. 2006 Feb;45(2):147-53 [16235244.001]

[Cites] RNA. 2006 May;12(5):733-50 [16540699.001]

[Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]

(PMID = 20844043.001).

[ISSN] 1098-5514

[Journal-full-title] Journal of virology

[ISO-abbreviation] J. Virol.

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / T32 AI007392; United States / NIAID NIH HHS / AI / P30-AI045008; United States / NIAID NIH HHS / AI / R01-AI067968; United States / NIAID NIH HHS / AI / R01 AI067968; United States / NCI NIH HHS / CA / T32-CA0009111; United States / NIAID NIH HHS / AI / P30 AI045008; United States / NCI NIH HHS / CA / T32 CA009111; United States / NIAID NIH HHS / AI / T32-AI007392; United States / NCI NIH HHS / CA / K99 CA137860-01A1; United States / NCI NIH HHS / CA / K99 CA137860; United States / NCI NIH HHS / CA / K99-CA137860

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / MIRN155 microRNA, human; 0 / MicroRNAs

[Other-IDs] NLM/ PMC2977875

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related lymphoproliferative disease.

Not long after the recognition of HIV as the causative agent of AIDS, it was evident that individuals infected with HIV developed lymphoma at a greater rate than the population at large.

Approximately two thirds of AIDS-related lymphoma (ARL) cases are categorized as diffuse large B-cell type, with Burkitt lymphomas comprising 25% and other histologies a much smaller proportion.

Typically, these individuals have presented with advanced extranodal disease and CD4+ lymphocyte counts of less than 200/mm3.

Coinfection with other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the genesis of previously rare or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.

Significant progress has been made in the understanding and management of ARL but outcomes still remain inferior compared to those achieved in HIV- individuals.

[MeSH-major] Lymphoma, AIDS-Related / therapy

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16099881.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 100

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary pulmonary AIDS-related lymphoma.

Extranodal involvement is common in lymphomas associated with human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS).

However, primary pulmonary AIDS-related non-Hodgkin's lymphoma is very rare and only few reports were published in the medical literature.

Primary pulmonary lymphoma associated with AIDS is generally a high-grade B-cell non-Hodgkin lymphoma and Epstein-Barr virus is strongly associated with the pathogenesis of these tumors.

We report a patient with AIDS and primary pulmonary lymphoma which clinical presentation was a total atelectasis of the left lung.

[MeSH-major] Lung Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Atelectasis / etiology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Collapsed Lung.

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16138208.001).

[ISSN] 0036-4665

[Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo

[ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The CD38 molecule is well represented on cell surfaces in many cases of a variety of lymphoid tumors, notably multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferations.

[MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Cell Line, Tumor. Humans. Leukemia / immunology. Lymphoma, B-Cell / immunology. Mice. Mice, SCID. Multiple Myeloma / immunology. Transplantation, Heterologous

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leuk Res. 2001 Jan;25(1):1-12 [11137554.001]

[Cites] Mol Cancer Ther. 2004 Mar;3(3):345-52 [15026555.001]

[Cites] Scand J Immunol. 1978 Apr;7(4):297-306 [418499.001]

[Cites] Am J Hematol. 1990 Feb;33(2):101-9 [2301368.001]

[Cites] Blood. 1991 Mar 1;77(5):1071-9 [1995092.001]

[Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):352-6 [8380497.001]

[Cites] Blood. 1994 Sep 1;84(5):1442-9 [7520771.001]

[Cites] Blood. 1994 Nov 1;84(9):3017-25 [7524764.001]

[Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]

[Cites] Leuk Res. 2007 Apr;31(4):455-63 [16920192.001]

(PMID = 17380203.001).

[ISSN] 1076-1551

[Journal-full-title] Molecular medicine (Cambridge, Mass.)

[ISO-abbreviation] Mol. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.2.2.5 / Antigens, CD38

[Other-IDs] NLM/ PMC1829201

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignant lymphomas (ML) and HIV infection in Tanzania.

BACKGROUND: HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.

The ML frequency, pathogenicity, clinical patterns and possible association with AIDS in Tanzania, are not well documented impeding the development of preventive and therapeutic strategies.

Available sera from 38 ML patients were screened (ELISA) for HIV antibodies.

RESULTS: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin's disease (HD).

The ML tumors frequency increased from 0.42% (1997) to 0.70% (2001) and 23.7% of tested sera from these patients were HIV positive.

Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) were diagnosed.

CONCLUSION: Malignant lymphomas apparently, increased significantly among diagnosed tumors at MNH between 1996 and 2001, predominantly among the young, HIV infected and AIDS patients.

The frequent aggressive clinical and histological presentation as well as the dominant B-immunophenotype and the HIV serology indicate a pathogenic association with AIDS.

Therefore, routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.

[MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / virology. Child. Child, Preschool. Female. HIV Seropositivity. Hodgkin Disease / epidemiology. Hodgkin Disease / etiology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Med Clin (Barc). 2000 Jan 15;114(1):19-21 [10782456.001]

[Cites] Trop Doct. 2008 Jan;38(1):7-11 [18302850.001]

[Cites] Med Trop (Mars). 1999;59(4 Pt 2):499-502 [10901854.001]

[Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]

[Cites] Curr Opin Oncol. 2000 Sep;12(5):383-94 [10975544.001]

[Cites] Med Oncol. 2001;18(1):15-22 [11778965.001]

[Cites] AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):383-90 [11897040.001]

[Cites] East Afr Med J. 2000 Aug;77(8):435-9 [12862069.001]

[Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]

[Cites] East Afr Med J. 1966 Jul;43(7):274-83 [5911333.001]

[Cites] Br Med Bull. 1971 Jan;27(1):14-20 [5100946.001]

[Cites] Cancer. 1980 Jul 1;46(1):186-9 [6893012.001]

[Cites] Acta Pathol Microbiol Scand A. 1981 Nov;89(6):417-24 [6278823.001]

[Cites] East Afr Med J. 1982 Apr;59(4):256-60 [7140611.001]

[Cites] Ann Trop Paediatr. 1984 Jun;4(2):83-5 [6083750.001]

[Cites] IARC Sci Publ. 1985;(60):155-64 [4065944.001]

[Cites] Cancer. 1991 Apr 1;67(7):1865-73 [2004300.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]

[Cites] Curr Opin Oncol. 1994 Sep;6(5):489-91 [7827151.001]

[Cites] Semin Diagn Pathol. 1997 Feb;14(1):48-53 [9044509.001]

[Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]

[Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]

[Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]

[Cites] Blood. 1999 Feb 15;93(4):1364-71 [9949180.001]

[Cites] Bull Cancer. 1999 Jun;86(6):529-36 [10417426.001]

[Cites] J Pak Med Assoc. 1999 Jan;49(1):11-5 [10463009.001]

[Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]

[Cites] East Afr Med J. 2004 Aug;(8 Suppl):S63-7 [15622604.001]

[Cites] East Afr Med J. 2004 Aug;(8 Suppl):S90-6 [15622607.001]

[Cites] East Afr Med J. 2004 Aug;81(8):384-7 [15622930.001]

[Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]

[Cites] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]

[Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]

[Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]

[Cites] Curr HIV/AIDS Rep. 2005 Aug;2(3):146-53 [16091262.001]

[Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]

[Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]

[Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]

[Cites] Oncol Rep. 2007 Jun;17(6):1291-9 [17487381.001]

[Cites] Int J Cancer. 2007 Oct 15;121(8):1806-12 [17557295.001]

[Cites] Cancer Sci. 2008 Feb;99(2):345-9 [18201268.001]

[Cites] Malays J Pathol. 1999 Jun;21(1):45-50 [10879278.001]

(PMID = 18577266.001).

[ISSN] 1756-9966

[Journal-full-title] Journal of experimental & clinical cancer research : CR

[ISO-abbreviation] J. Exp. Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Other-IDs] NLM/ PMC2438337

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression.

HIV-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin Lymphoma relative to HIV(-) persons.

Due to their aggressive nature, AIDS-related lymphomas (ARL) can also be more difficult to classify.

Genetic abnormalities are known to play a significant role in HIV(-) lymphomagenesis.

Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt lymphoma and diffuse large B-cell lymphoma, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell lymphoma.

These data demonstrate the ability to molecularly classify B-ARL lymphomas by gene expression and identified DNA copy number alterations targeted in B-ARL.

[MeSH-major] Chromosome Aberrations. Gene Dosage. Gene Expression. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology

[MeSH-minor] Adult. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

SciCrunch. ArrayExpress: Data: Microarray .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20216076.001).

[ISSN] 1944-7884

[Journal-full-title] Journal of acquired immune deficiency syndromes (1999)

[ISO-abbreviation] J. Acquir. Immune Defic. Syndr.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [HIV-related multiple non-Hodgkin lymphomas].

He was HIV-positive, and had gastric diffuse large B-cell lymphoma and renal T-cell anaplastic large cell lymphoma (T-ALCL).

We diagnosed double lymphomas related to AIDS.

The patient received anti-retroviral therapy, and started the CHOP regimen for the double lymphomas, resulting in transient improvement.

Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple lymphomas.

This case suggested that cancer generation was promoted by low immunity, although it is known that ambivalent tumors such as non-Hodgkin lymphomas can occur frequently.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Stomach Cancer.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19047787.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.

Human immunodeficiency virus-infected patients are at an increased risk for developing both Hodgkin and non-Hodgkin lymphoma when compared with the general population.

With the remarkable decrease in the incidence of opportunistic infections since the availability of highly active antiretroviral therapy (HAART), acquired immune deficiency syndrome-related lymphoma (ARL) is now the second most common cancer associated with human immunodeficiency virus after Kaposi sarcoma.

Over the last few years, advances in our understanding of the molecular biology of this heterogeneous group of lymphomas have led to the adoption of new classification systems.

Apart from the contribution of HAART, this improvement in prognosis can also be attributed to new initiatives in treatment of these patients, such as the use of effective infusional regimens, the feasibility of high-dose therapy with peripheral stem cell rescue for relapsed or refractory disease, and better supportive care.

Nonetheless, several controversial issues persist, including the optimal timing of HAART with combination chemotherapy, the role of rituximab when incorporated into treatment regimens, and the optimal therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma.

[MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology

[MeSH-minor] AIDS-Related Opportunistic Infections. Drug Administration Schedule. Humans. Incidence. Peripheral Blood Stem Cell Transplantation. Prevalence. Prognosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16020424.001).

[ISSN] 0007-9235

[Journal-full-title] CA: a cancer journal for clinicians

[ISO-abbreviation] CA Cancer J Clin

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 52

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions.

PURPOSE OF REVIEW: We discuss recently published studies that elucidate the pathogenesis of AIDS-associated lymphoma.

RECENT FINDINGS: Several recent reports have provided valuable new information on the role of gamma-herpesviruses in the pathogenesis of AIDS-associated lymphoma.

In addition to this, significant new information has become available on how B cell activation-associated DNA-modifying events, involving activation-induced cytidine deaminase and DNA polymerase-eta, contribute to the molecular lesions that result in AIDS-associated lymphoma.

In particular, new evidence that oncogenic viruses can directly induce activation-induced cytidine deaminase expression and oncogene mutation in human B cells is of central relevance to better understanding the pathogenesis of AIDS-associated lymphoma.

SUMMARY: New information provides insights into the contributions of immune dysfunction and oncogenic virus infection to pathogenesis of AIDS-associated lymphoma, and may lead to new potential targets for therapeutic intervention in these cancers.

[MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / virology. Lymphoma, B-Cell / genetics. Oncogenic Viruses / pathogenicity

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16894291.001).

[ISSN] 1040-8746

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] eng

[Grant] United States / NIAID NIH HHS / AI / AI35040; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA70080; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 2.7.7.7 / Rad30 protein; EC 3.5.4.5 / Cytidine Deaminase

[Number-of-references] 28

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma.

In advanced stages, cutaneous T cell lymphomas (CTCL) are associated with increased mortality from infections and also increased susceptibility to skin malignancies.

Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Dermatol. 2003 Feb;42(2):116-22 [12708999.001]

[Cites] AIDS. 2003 May 2;17(7):947-54 [12700443.001]

[Cites] Blood. 2003 Dec 1;102(12):4059-66 [12829591.001]

[Cites] N Engl J Med. 2004 Feb 19;350(8):757-66 [14973217.001]

[Cites] J Am Acad Dermatol. 2004 May;50(5):701-5 [15097953.001]

[Cites] J Exp Med. 2004 Sep 20;200(6):749-59 [15365096.001]

[Cites] J Am Acad Dermatol. 1981 Feb;4(2):176-80 [7217388.001]

[Cites] J Dermatol. 1990 Aug;17(8):477-81 [2229651.001]

[Cites] JAMA. 1992 Mar 11;267(10):1354-8 [1740857.001]

[Cites] J Invest Dermatol. 1992 Jul;99(1):90-4 [1607682.001]

[Cites] Blood. 1996 Aug 15;88(4):1383-9 [8695857.001]

[Cites] Arch Dermatol Res. 1996 Dec;289(1):9-13 [9017129.001]

[Cites] Pediatr Res. 1998 Mar;43(3):396-402 [9505280.001]

[Cites] Blood. 2005 Feb 15;105(4):1640-7 [15514008.001]

[Cites] J Clin Invest. 2005 Apr;115(4):798-812 [15841167.001]

[Cites] Clin Cancer Res. 2005 Aug 15;11(16):5748-55 [16115912.001]

[Cites] Clin Cancer Res. 2006 Jan 15;12(2):376-82 [16428475.001]

[Cites] Blood. 2006 Mar 15;107(6):2440-5 [16322477.001]

[Cites] Infection. 2008 Mar;36(2):120-9 [18379725.001]

[Cites] Clin Lymphoma Myeloma. 2008 Apr;8(2):100-5 [18501103.001]

[Cites] Semin Immunol. 2008 Jun;20(3):196-203 [18757210.001]

[Cites] J Am Acad Dermatol. 2008 Dec;59(6):949-52 [18835065.001]

[Cites] Blood. 2000 Jan 1;95(1):352-9 [10607724.001]

[Cites] Nat Biotechnol. 2000 Jul;18(7):729-34 [10888839.001]

[Cites] Nat Immunol. 2000 Aug;1(2):132-7 [11248805.001]

[Cites] J Am Acad Dermatol. 2001 Aug;45(2):208-16 [11464181.001]

[Cites] Blood. 2001 Aug 15;98(4):1116-21 [11493459.001]

[Cites] Hum Immunol. 2002 Jan;63(1):51-60 [11916170.001]

[Cites] Clin Exp Immunol. 2003 Apr;132(1):105-12 [12653844.001]

[Cites] Arch Dermatol. 2003 Jul;139(7):909-13 [12873887.001]

(PMID = 20111968.001).

[ISSN] 1432-069X

[Journal-full-title] Archives of dermatological research

[ISO-abbreviation] Arch. Dermatol. Res.

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / AI041707-12; United States / NCI NIH HHS / CA / P50 CA093683-07; United States / NIAID NIH HHS / AI / R01 AI041707-12; United States / NCI NIH HHS / CA / P50 CA093683; United States / NIAID NIH HHS / AI / R01 AI041707

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] Germany

[Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Receptors, Antigen, T-Cell; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox

[Other-IDs] NLM/ NIHMS190229; NLM/ PMC2892560

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.

It still needs to be clarified whether P-gp expression has a significant impact on non-Hodgkin's lymphoma treatment response, but a poor outcome has been reported in patients with positive P-gp expression.

AIDS-related lymphomas have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.

In an attempt to determine a possible relationship between MDR and poor outcome in this population, histologic samples obtained from 45 non-Hodgkin's lymphoma HIV-infected patients without previous cytotoxic therapy were submitted to immunohistochemical analysis using monoclonal antibody C494 specific for the MDR-1 isoform of P-gp.

In patients having achieved complete remission, the median disease-free survival (DFS) was not reached; the mean DFS was 57.2 months with DFS rates of 72.9% in three years.

Our results show that P-gp is expressed before treatment of non-Hodgkin's lymphoma of HIV patients, and is related to poor response to treatment and overall survival.

[MeSH-major] Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related / metabolism. P-Glycoprotein / biosynthesis

[MeSH-minor] Adolescent. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Pathol Res Pract. 2007;203(10):763

(PMID = 17157997.001).

[ISSN] 0344-0338

[Journal-full-title] Pathology, research and practice

[ISO-abbreviation] Pathol. Res. Pract.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas.

OBJECTIVE: The aim of this study was to determine the occurrence of polymorphic variants of EBV BamHI fragment Z (BZLF1) promoter zone Zp in tumor and non-tumor-associated EBV.

We characterized the Zp region in type A and type B EBV, infecting AIDS-related non-Hodgkin's lymphomas (AIDS-NHL) and non-malignant lymphoid tissues derived from HIV-positive patients and from healthy individuals.

METHODS: The Zp region was directly sequenced in 133 EBV-positive DNA samples: 63 AIDS-NHL (32 systemic AIDS-NHL and 31 AIDS-primary central nervous system lymphoma [AIDS-PCNSL]), 30 lymphoid tissues derived from HIV-positive individuals and 40 lymphoid samples derived from healthy individuals.

Zp-V3 was significantly associated with AIDS-PCNSL (P<0.001) and with systemic AIDS-NHL (P=0.007), in particular with AIDS-related immunoblastic lymphoma (P<0.001).

Moreover, in malignant samples, this variant was also significantly associated with type B EBV (P<0.001).

Finally, the new identified Zp-PV variant was isolated in 7 AIDS-PCNSL.

CONCLUSIONS: The frequency of polymorphisms in the regulatory zone of BZLF1 is different between malignant and non-malignant samples in AIDS patients and may identify EBV subtypes with different transforming activities, including those associated to the pathogenesis of B cell lymphoma.

[MeSH-major] Acquired Immunodeficiency Syndrome / virology. DNA-Binding Proteins / genetics. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics. Lymphoma / virology. Promoter Regions, Genetic. Trans-Activators / genetics. Viral Proteins / genetics

[MeSH-minor] DNA, Viral / genetics. Humans. Lymphoid Tissue / virology. Lymphoma, AIDS-Related / virology. Polymorphism, Genetic. Sequence Analysis, DNA. Statistics as Topic

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Lymphoma.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16784778.001).

[ISSN] 1532-2742

[Journal-full-title] The Journal of infection

[ISO-abbreviation] J. Infect.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / BZLF1 protein, Herpesvirus 4, Human; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Trans-Activators; 0 / Viral Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.

BACKGROUND: Neurological disorders are common in HIV-infected patients.

Central nervous system (CNS) lymphoma should always be considered because it is an important cause of morbidity and mortality.

OBJECTIVES: To investigate the clinical utility of flow cytometry immunophenotyping (FCI) in diagnosing or discarding leptomeningeal involvement in HIV-infected patients and to compare its sensitivity with that of conventional cytological methods.

METHODS: Fifty-six cerebrospinal fluid (CSF) samples from 29 HIV-infected patients were independently evaluated by flow cytometry and cytology.

RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.

This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin's lymphoma should be strongly considered.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis

[MeSH-minor] Adult. Burkitt Lymphoma / cerebrospinal fluid. Burkitt Lymphoma / diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15670248.001).

[ISSN] 1464-2662

[Journal-full-title] HIV medicine

[ISO-abbreviation] HIV Med.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.

In some subtypes of non-Hodgkin's lymphomas, higher local vascular endothelial growth factor (VEGF) expression correlates with increased microvessel density.

Several studies have indicated that VEGF receptors are also targeted by Tat protein from the HIV-1-infected cells.

We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the AIDS-related diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL).

Reduced VEGF protein expression in primary HIV-1 positive BL and DLBCL, compared to the negative cases, supported the findings of promoter downregulation from the cell lines.

Microvascular density assessed by CD34 expression was, however, higher in HIV-1 positive than in HIV-1 negative tumors.

Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the AIDS-associated tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the AIDS-associated non-Hodgkin's lymphomas.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Med. 1996 Dec;2(12):1371-5 [8946838.001]

[Cites] Oncogene. 2000 Jan 20;19(3):373-9 [10656684.001]

[Cites] Oncogene. 1996 Jan 18;12(2):289-97 [8570206.001]

[Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]

[Cites] Leuk Lymphoma. 2007 Oct;48(10):2014-21 [17917969.001]

[Cites] Br J Cancer. 2007 Jul 16;97(2):223-30 [17595666.001]

[Cites] Exp Cell Res. 2007 May 1;313(8):1561-74 [17382929.001]

[Cites] Am J Pathol. 2007 Apr;170(4):1362-9 [17392174.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52 [17360578.001]

[Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):693-9 [17320821.001]

[Cites] Nat Struct Mol Biol. 2007 Mar;14(3):249-50 [17293873.001]

[Cites] J Cell Biochem. 2007 Feb 15;100(3):727-37 [17115409.001]

[Cites] Curr Med Chem. 2006;13(16):1845-57 [16842197.001]

[Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]

[Cites] Folia Histochem Cytobiol. 2004;42(4):241-3 [15704651.001]

[Cites] Biochem Pharmacol. 2004 Dec 15;68(12):2359-66 [15548382.001]

[Cites] Circulation. 1997 Dec 2;96(11):4083-94 [9403634.001]

[Cites] J Biol Chem. 1998 Nov 20;273(47):31119-24 [9813014.001]

[Cites] Science. 1998 Dec 4;282(5395):1837-9 [9874635.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]

[Cites] J Clin Pathol. 1997 Jun;50(6):481-4 [9378813.001]

[Cites] Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5 [7542074.001]

[Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]

[Cites] Nature. 1994 Oct 20;371(6499):674-80 [7935812.001]

[Cites] Arch Orthop Trauma Surg. 2003 Nov;123(9):475-80 [12750926.001]

[Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]

[Cites] Cell Prolif. 2003 Jun;36(3):131-49 [12814430.001]

[Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]

[Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]

[Cites] J Rheumatol. 2003 Feb;30(2):260-8 [12563678.001]

[Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]

[Cites] Hum Pathol. 2002 Jul;33(7):723-31 [12196924.001]

[Cites] Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44 [11965229.001]

[Cites] Clin Microbiol Rev. 2002 Apr;15(2):310-26 [11932235.001]

[Cites] Am J Clin Pathol. 2001 Dec;116(6):838-45 [11764072.001]

[Cites] Biochem J. 2001 Feb 1;353(Pt 3):569-78 [11171054.001]

[Cites] Cancer Res. 2001 Jan 15;61(2):462-8 [11212232.001]

[Cites] Curr Opin Oncol. 2000 Sep;12(5):445-9 [10975552.001]

[Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):267-71 [10873597.001]

[Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]

[Cites] Am J Pathol. 1996 Apr;148(4):1065-74 [8644848.001]

(PMID = 19669199.001).

[ISSN] 1868-9256

[Journal-full-title] Journal of hematopathology

[ISO-abbreviation] J Hematop

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Other-IDs] NLM/ PMC2712328

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-associated lymphomas and gamma-herpesviruses.

Among the most common HIV-associated lymphomas are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with immunoblastic-plasmacytoid differentiation (also involving the central nervous system).

Lymphomas occurring specifically in HIV-positive patients include primary effusion lymphoma (PEL) and its solid variants, plasmablastic lymphoma of the oral cavity type and large B-cell lymphoma arising in Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease.

These lymphomas together with BL and DLBCL with immunoblastic-plasmacytoid differentiation frequently carry EBV infection and display a phenotype related to plasma cells.

EBV infection occurs at different rates in different lymphoma types, whereas KSHV is specifically associated with PEL, which usually occurs in the setting of profound immunosuppression.

The current knowledge about HIV-associated lymphomas can be summarized in the following key points:.

(1) lymphomas specifically occurring in patients with HIV infection are closely linked to other viral diseases;.

(2) AIDS lymphomas fall in a spectrum of B-cell differentiation where those associated with EBV or KSHV commonly exhibit plasmablastic differentiation; and (3) prognosis for patients with lymphomas and concomitant HIV infection could be improved using better combined chemotherapy protocols incorporating anticancer treatments and antiretroviral drugs.

[MeSH-major] Gammaherpesvirinae / pathogenicity. HIV-1 / pathogenicity. Herpesviridae Infections / virology. Lymphoma, AIDS-Related / virology

Genetic Alliance. consumer health - HIV.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18955561.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents

[Number-of-references] 162

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma.

Kaposi sarcoma-associated herpesvirus (KSHV) is a human lymphotropic herpesvirus.

It is implicated in B cell neoplasias such as primary effusion lymphoma and multicentric Castleman disease in AIDS patients.

The KSHV latency-associated nuclear antigen (LANA) is consistently expressed in all KSHV-associated tumor cells and was shown to bind the tumor suppressor proteins p53 and pRb.

We also observed lymphomas, implying that LANA can activate B cells and provide the first step toward lymphomagenesis.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

SciCrunch. Marmoset Gene list: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]

[Cites] J Virol. 2002 Nov;76(21):11024-32 [12368345.001]

[Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]

[Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]

[Cites] J Virol. 2003 Jun;77(11):6474-81 [12743304.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]

[Cites] J Clin Invest. 2004 Jan;113(1):124-36 [14702116.001]

[Cites] Cancer Res. 2004 Jan 15;64(2):581-9 [14744772.001]

[Cites] Br J Cancer. 2004 Jun 1;90(11):2145-8 [15150582.001]

[Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]

[Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]

[Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]

[Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(12):4781-4 [2352948.001]

[Cites] EMBO J. 1992 May;11(5):1891-9 [1582417.001]

[Cites] Eur J Immunol. 1992 Nov;22(11):3001-11 [1425924.001]

[Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]

[Cites] J Exp Med. 1996 Jul 1;184(1):283-8 [8691144.001]

[Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]

[Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]

[Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]

[Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

[Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]

[Cites] Cancer Res. 2005 Apr 1;65(7):2626-35 [15805259.001]

[Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]

[Cites] Cancer Cell. 2005 May;7(5):445-55 [15894265.001]

[Cites] Cancer Res. 2005 Jul 1;65(13):5925-34 [15994971.001]

[Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]

[Cites] J Exp Med. 1999 Dec 20;190(12):1857-68 [10601360.001]

[Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]

[Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]

[Cites] J Immunol. 2000 Feb 15;164(4):1961-70 [10657646.001]

[Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]

[Cites] J Virol. 2001 Jan;75(1):458-68 [11119614.001]

[Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]

[Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]

[Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24 [11274437.001]

[Cites] J Biol Chem. 2001 Jun 22;276(25):22971-8 [11313352.001]

[Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]

[Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]

[Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]

[Cites] Clin Microbiol Rev. 2002 Jul;15(3):439-64 [12097251.001]

[Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]

(PMID = 16498502.001).

[ISSN] 0021-9738

[Journal-full-title] The Journal of clinical investigation

[ISO-abbreviation] J. Clin. Invest.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / CA109232

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen

[Other-IDs] NLM/ PMC1378187

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Epstein-Barr virus (EBV) causes EBV-associated lymphoproliferative diseases in patients with profound immune suppression.

Most of these diseases are life-threatening and the prognosis of AIDS-associated lymphomas is extremely unfavorable.

We investigated the possibility of nuclear factor kappa B (NF-kappaB) inhibition by dehydroxymethylepoxyquinomicin (DHMEQ) for the treatment and prevention of EBV-associated lymphoproliferative diseases.

These results suggest that NF-kappaB is a molecular target for the treatment and prevention of EBV-associated lymphoproliferative diseases.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18538617.001).

[ISSN] 1286-4579

[Journal-full-title] Microbes and infection

[ISO-abbreviation] Microbes Infect.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / Immunologic Factors; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in Southeast Asia and is strongly associated with Epstein-Barr virus (EBV).

The presence of circulating tumor cells was assessed by amplification of BamHI-A rightward frame 1 (BARF1) mRNA, a viral oncogene abundantly expressed in EBV-carrying carcinomas but virtually absent from EBV-associated lymphomas.

Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 1999 Nov 1;59(21):5452-5 [10554016.001]

[Cites] Clin Cancer Res. 2000 Mar;6(3):1046-51 [10741733.001]

[Cites] Cancer Res. 2000 May 15;60(10):2745-8 [10825150.001]

[Cites] J Virol. 2000 Oct;74(19):9078-82 [10982353.001]

[Cites] Klin Padiatr. 2000 Jul-Aug;212(4):206-10 [10994552.001]

[Cites] J Gen Virol. 2000 Oct;81(Pt 10):2417-23 [10993929.001]

[Cites] Cancer Res. 2000 Oct 1;60(19):5584-8 [11034107.001]

[Cites] J Virol. 2000 Nov;74(22):10681-9 [11044112.001]

[Cites] Protein Expr Purif. 2000 Nov;20(2):324-33 [11049756.001]

[Cites] J Virol Methods. 2000 Nov;90(2):193-204 [11064119.001]

[Cites] Mol Pathol. 2000 Oct;53(5):248-54 [11091848.001]

[Cites] Blood. 2000 Dec 15;96(13):4055-63 [11110673.001]

[Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]

[Cites] J Mol Diagn. 2000 Nov;2(4):191-201 [11232109.001]

[Cites] Blood. 2001 Mar 1;97(5):1165-71 [11222357.001]

[Cites] J Clin Microbiol. 2001 Apr;39(4):1211-6 [11283029.001]

[Cites] J Clin Oncol. 2001 May 15;19(10):2607-15 [11352952.001]

[Cites] Clin Cancer Res. 2002 Feb;8(2):433-7 [11839660.001]

[Cites] Cancer. 2002 Feb 1;94(3):723-9 [11857305.001]

[Cites] Mol Biotechnol. 2002 Feb;20(2):163-79 [11876473.001]

[Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]

[Cites] AIDS. 2002 May 3;16(7):993-1001 [11953465.001]

[Cites] Leuk Lymphoma. 2002 Apr;43(4):831-40 [12153173.001]

[Cites] Clin Cancer Res. 2002 Aug;8(8):2612-9 [12171892.001]

[Cites] J Clin Microbiol. 2002 Nov;40(11):3986-92 [12409363.001]

[Cites] J Clin Microbiol. 2002 Nov;40(11):4105-13 [12409382.001]

[Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9 [12419787.001]

[Cites] Semin Cancer Biol. 2002 Dec;12(6):431-41 [12450729.001]

[Cites] Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36 [12482570.001]

[Cites] J Clin Virol. 2003 Oct;28(2):155-64 [12957185.001]

[Cites] Clin Cancer Res. 2003 Aug 15;9(9):3254-9 [12960110.001]

[Cites] Clin Cancer Res. 2003 Aug 15;9(9):3431-4 [12960133.001]

[Cites] J Clin Microbiol. 2003 Nov;41(11):5245-9 [14605174.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44 [14688409.001]

[Cites] Cancer. 2004 Mar 15;100(6):1162-70 [15022282.001]

[Cites] Cancer. 2004 Apr 1;100(7):1429-37 [15042677.001]

[Cites] Cancer Sci. 2004 Jun;95(6):508-13 [15182432.001]

[Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]

[Cites] J Infect Dis. 2004 Jul 1;190(1):53-62 [15195243.001]

[Cites] Oncogene. 2004 Jun 17;23(28):4938-44 [15064715.001]

[Cites] Methods Mol Biol. 2005;292:15-26 [15507698.001]

[Cites] Int J Cancer. 1976 Jan 15;17(1):1-7 [175020.001]

[Cites] Int J Cancer. 1977 Nov 15;20(5):655-62 [200568.001]

[Cites] J Gen Virol. 1985 Sep;66 ( Pt 9):1931-40 [2993484.001]

[Cites] J Virol. 1987 Dec;61(12):3870-8 [2824821.001]

[Cites] Nature. 1989 May 18;339(6221):237-8 [2716852.001]

[Cites] EMBO J. 1989 Oct;8(10):2897-903 [2555151.001]

[Cites] J Clin Microbiol. 1990 Mar;28(3):495-503 [1691208.001]

[Cites] Oncogene. 1993 Jun;8(6):1575-83 [8389032.001]

[Cites] J Clin Microbiol. 1997 Jun;35(6):1612-5 [9163497.001]

[Cites] Oncogene. 1997 Jun 26;14(25):3073-81 [9223671.001]

[Cites] J Virol Methods. 1997 Sep;67(2):199-207 [9300385.001]

[Cites] Clin Chem. 1997 Oct;43(10):1843-9 [9342002.001]

[Cites] Clin Cancer Res. 1998 Mar;4(3):665-9 [9533535.001]

[Cites] J Med Virol. 1998 Jul;55(3):227-33 [9624611.001]

[Cites] J Virol Methods. 1998 Jun;72(2):175-84 [9694325.001]

[Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]

[Cites] J Clin Microbiol. 1998 Nov;36(11):3164-9 [9774558.001]

[Cites] J Clin Microbiol. 1999 Sep;37(9):2852-7 [10449464.001]

[Cites] Mol Pathol. 1999 Apr;52(2):97-103 [10474689.001]

[Cites] Transpl Infect Dis. 2001 Jun;3(2):79-87 [11395973.001]

[Cites] Clin Cancer Res. 2003 Mar;9(3):1033-8 [12631603.001]

[Cites] Cell Death Differ. 2003 Jan;10(1):108-16 [12655299.001]

[Cites] Cancer Res. 2003 May 1;63(9):2028-32 [12727814.001]

[Cites] Int J Cancer. 2003 Jul 10;105(5):706-9 [12740922.001]

[Cites] Cancer. 2003 Jul 15;98(2):288-91 [12872347.001]

(PMID = 16002393.001).

[ISSN] 0095-1137

[Journal-full-title] Journal of clinical microbiology

[ISO-abbreviation] J. Clin. Microbiol.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / RNA, Messenger

[Other-IDs] NLM/ PMC1169169

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Study of the morphological patterns and association of Epstein-Barr virus and human herpes virus 8 in acquired immunodeficiency deficiency syndrome-related reactive lymphadenopathy.

AIMS: Study of the morphological patterns of acquired immunodeficiency syndrome (AIDS)-related lymphadenopathy.

SETTINGS AND DESIGN: We retrospectively selected cases of AIDS-related benign lymphadenopathy.

Cases with lymphomas, frank granulomas and necrosis were excluded.

We analyzed different morphological patterns and correlated these with immunophenotypic markers along with viral markers human herpesvirus 8-latency-associated nuclear antigen (HHV8-LANA), and Epstein-Barr virus-encoded ribonucleic acid (EBER) studies via in situ hybridization (EBER-ISH).

MATERIALS AND METHODS: We present the morphological patterns of 13 cases of human immunodeficiency virus (HIV)-reactive lymph nodes and their clinical, hematological, biochemical and radiological parameters with special emphasis on the presence or absence of viral markers, including HHV8 and EBV.

Two cases of multicentric Castleman's disease expressed EBER; however, they did not express HHV8.

CONCLUSION: The wide spectrum of histological changes in HIV-associated lymphadenopathy requires recognition.

The histological changes can mimic those of other infective lymphadenitis, follicular lymphoma, Castleman's disease, progressive transformation of germinal center, Hodgkin's disease and spindle cell neoplasms.

[MeSH-major] AIDS-Related Opportunistic Infections / pathology. Epstein-Barr Virus Infections / pathology. HIV Infections / complications. Herpesviridae Infections / pathology. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Lymphatic Diseases / pathology

Genetic Alliance. consumer health - MYH9 related thrombocytopenia.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - Lymphatic Diseases.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21045401.001).

[ISSN] 0974-5130

[Journal-full-title] Indian journal of pathology & microbiology

[ISO-abbreviation] Indian J Pathol Microbiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Chemical-registry-number] 0 / Biomarkers

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.

HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL).

The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss of immune function seen in HIV infection, which results in the loss of immunoregulation of Epstein-Barr virus-infected B cells, as well as HIV infection-associated immune dysregulation, including chronic B-cell activation.

In this review, we discuss recent reports that further support the importance of these factors, and we highlight emerging evidence of different mechanisms that potentially drive lymphomagenesis in HIV-infected individuals.

[MeSH-major] AIDS-Related Opportunistic Infections / immunology. Acquired Immunodeficiency Syndrome / immunology. B-Lymphocytes / immunology. Epstein-Barr Virus Infections / immunology. HIV / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]

[Cites] Immunity. 2000 Oct;13(4):485-95 [11070167.001]

[Cites] J Virol. 2001 Jul;75(13):6173-82 [11390619.001]

[Cites] AIDS. 2001 May 25;15(8):957-64 [11399977.001]

[Cites] Blood. 2001 Jul 1;98(1):146-55 [11418474.001]

[Cites] Eur J Immunol. 2001 May;31(5):1544-9 [11465112.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4730-5 [12665622.001]

[Cites] Tumour Biol. 2003 Mar-Apr;24(2):82-93 [12853703.001]

[Cites] Nat Rev Immunol. 2003 Aug;3(8):609-20 [12974476.001]

[Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]

[Cites] J Immunol. 2003 Nov 15;171(10):5215-24 [14607922.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 [14999097.001]

[Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]

[Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(11):3456-60 [6222380.001]

[Cites] Science. 1986 Sep 5;233(4768):1084-6 [3016902.001]

[Cites] J Immunol. 1987 Jun 1;138(11):3720-4 [2953790.001]

[Cites] Immunol Today. 1989 May;10(5):153-7 [2525911.001]

[Cites] J Exp Med. 1989 Dec 1;170(6):2081-95 [2531194.001]

[Cites] Immunology. 1989 Dec;68(4):526-31 [2481643.001]

[Cites] AIDS. 1992 Oct;6(10):1105-16 [1466841.001]

[Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]

[Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]

[Cites] Blood. 1993 Dec 1;82(11):3430-6 [8241510.001]

[Cites] Eur J Immunol. 1994 Aug;24(8):1869-73 [8056045.001]

[Cites] Immunol Today. 1994 Sep;15(9):418-22 [7524519.001]

[Cites] J Immunol. 1995 Mar 15;154(6):2533-44 [7533177.001]

[Cites] Blood. 1995 Apr 1;85(7):1843-9 [7703491.001]

[Cites] Mol Med. 1995 Jul;1(5):495-505 [8529116.001]

[Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]

[Cites] Leuk Lymphoma. 1998 Jul;30(3-4):257-67 [9713958.001]

[Cites] Clin Immunol. 1999 Feb;90(2):157-64 [10080826.001]

[Cites] Blood. 1999 Jul 1;94(1):275-82 [10381523.001]

[Cites] Clin Immunol. 1999 Sep;92(3):293-9 [10479534.001]

[Cites] Clin Immunol. 1999 Nov;93(2):114-23 [10527687.001]

[Cites] J Immunol. 2005 Jun 15;174(12):7912-9 [15944297.001]

[Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]

[Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]

[Cites] J Interferon Cytokine Res. 2005 Nov;25(11):702-6 [16318584.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18093-8 [16330748.001]

[Cites] J Immunol. 2006 Apr 1;176(7):3931-41 [16547227.001]

[Cites] RNA. 2006 May;12(5):733-50 [16540699.001]

[Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]

[Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]

[Cites] Mol Immunol. 2007 Jan;44(4):494-505 [16574227.001]

[Cites] Mol Immunol. 2007 Feb;44(5):934-42 [16730063.001]

[Cites] Blood. 2006 Dec 1;108(12):3859-64 [16882707.001]

[Cites] Ann Rheum Dis. 2007 Jan;66(1):23-7 [16569685.001]

[Cites] JAMA. 2006 Dec 20;296(23):2823-31 [17179459.001]

[Cites] Nat Med. 2007 Feb;13(2):139-45 [17290272.001]

[Cites] Blood. 2007 Mar 15;109(6):2545-52 [17132718.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12 [17360630.001]

[Cites] Transl Res. 2007 Apr;149(4):231-5 [17383597.001]

[Cites] J Virol. 2007 Jun;81(11):5872-81 [17392362.001]

[Cites] J Immunol. 2007 Jun 1;178(11):6730-3 [17513719.001]

[Cites] Nucleic Acids Res. 2007;35(10):e73 [17478510.001]

[Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]

[Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]

[Cites] J Immunol. 2007 Sep 1;179(5):3153-60 [17709530.001]

[Cites] AIDS. 2007 Nov 12;21(17):2265-70 [18090274.001]

[Cites] Nat Genet. 2008 Jan;40(1):108-12 [18066064.001]

[Cites] Cancer Res. 2008 Mar 1;68(5):1436-42 [18316607.001]

[Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]

[Cites] J Immunol. 2008 Jul 1;181(1):186-9 [18566383.001]

[Cites] Blood. 2008 Dec 1;112(12):4401-10 [18780835.001]

[Cites] Ann Rheum Dis. 2009 Jan;68(1):89-93 [18375535.001]

[Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]

[Cites] Int J Cancer. 2009 Apr 15;124(8):1745-55 [19165855.001]

[Cites] J Clin Oncol. 2009 Feb 20;27(6):967-73 [19114696.001]

[Cites] J Infect Dis. 2009 Jul 1;200(1):79-87 [19476437.001]

[Cites] Clin Cancer Res. 2009 Oct 1;15(19):5968-73 [19773382.001]

[Cites] Biochem Biophys Res Commun. 2009 Dec 11;390(2):269-72 [19799865.001]

[Cites] Mol Immunol. 2009 Nov;47(1):3-7 [19193443.001]

[Cites] Mol Cell. 2009 Nov 25;36(4):631-41 [19941823.001]

[Cites] Semin Cancer Biol. 2009 Dec;19(6):351-65 [19619654.001]

[Cites] Semin Cancer Biol. 2009 Dec;19(6):401-6 [19619656.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22421-6 [20080792.001]

[Cites] Int J Cancer. 2010 Mar 15;126(6):1316-26 [19530237.001]

[Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9 [19654554.001]

[Cites] J Clin Oncol. 2010 Feb 10;28(5):773-9 [20048176.001]

[Cites] Cytokine. 2010 Apr;50(1):58-68 [20060740.001]

[Cites] J Leukoc Biol. 2010 Apr;87(4):627-32 [20042471.001]

[Cites] AIDS. 2010 Apr 24;24(7):1025-33 [20299965.001]

[Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):18-26 [20216076.001]

[Cites] Cancer Immunol Immunother. 2010 Jul;59(7):979-87 [20352428.001]

[Cites] Br J Haematol. 2010 May;149(4):484-97 [20346013.001]

[Cites] Biochem Biophys Res Commun. 2010 May 21;396(1):67-73 [20494113.001]

[Cites] PLoS One. 2010;5(7):e11448 [20625427.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84 [10566552.001]

[Cites] Inflamm Bowel Dis. 1999 Nov;5(4):285-94 [10579123.001]

[Cites] Clin Immunol. 1999 Dec;93(3):239-44 [10600334.001]

[Cites] J Allergy Clin Immunol. 2000 May;105(5):975-82 [10808179.001]

[Cites] AIDS. 2000 Jul 7;14(10):1460-1 [10930167.001]

(PMID = 20717742.001).

[ISSN] 1559-0755

[Journal-full-title] Immunologic research

[ISO-abbreviation] Immunol. Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R01 CA073475

[Publication-type] Journal Article; Review

[Publication-country] United States

[Other-IDs] NLM/ NIHMS461037; NLM/ PMC3640300

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Role of the ubiquitin system and tumor viruses in AIDS-related cancer.

This review focuses on examples of human oncogenic viruses that manipulate the ubiquitin system in a subset of viral malignancies; those associated with AIDS.

The viruses include Kaposi's sarcoma herpesvirus, Epstein-Barr virus and human papilloma virus, which are causally linked to Kaposi's sarcoma, certain B-cell lymphomas and cervical cancer, respectively.

Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]

[Cites] Cell Cycle. 2004 Nov;3(11):1345-7 [15492505.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13057-62 [11087859.001]

[Cites] Acta Virol. 2000 Jun-Aug;44(3):211-26 [11155368.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23 [11158620.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1227-35 [11423255.001]

[Cites] J Virol. 2001 Aug;75(16):7583-91 [11462030.001]

[Cites] Oncogene. 2001 Aug 2;20(34):4740-9 [11498796.001]

[Cites] Chem Biol. 2001 Aug;8(8):739-58 [11514224.001]

[Cites] Am J Clin Pathol. 2001 Nov;116(5):637-46 [11710679.001]

[Cites] J Cell Biol. 2001 Dec 24;155(7):1265-73 [11756476.001]

[Cites] J Biol Chem. 2002 Feb 22;277(8):6124-30 [11751860.001]

[Cites] Nat Med. 2002 Apr;8(4):338-40 [11927937.001]

[Cites] EMBO J. 2002 May 15;21(10):2418-29 [12006494.001]

[Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]

[Cites] Oral Dis. 2002;8 Suppl 2:161-8 [12164651.001]

[Cites] Curr Top Microbiol Immunol. 2002;269:23-36 [12224511.001]

[Cites] Cancer Lett. 2002 Dec 15;188(1-2):15-24 [12406543.001]

[Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]

[Cites] Semin Cancer Biol. 2002 Dec;12(6):431-41 [12450729.001]

[Cites] Semin Cancer Biol. 2003 Feb;13(1):59-67 [12507557.001]

[Cites] Semin Cancer Biol. 2003 Feb;13(1):69-76 [12507558.001]

[Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]

[Cites] Carcinogenesis. 2003 Feb;24(2):159-69 [12584163.001]

[Cites] Hum Mutat. 2003 Mar;21(3):307-12 [12619117.001]

[Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]

[Cites] Med Sci (Paris). 2003 Jan;19(1):100-6 [12836198.001]

[Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi [12852651.001]

[Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]

[Cites] Isr Med Assoc J. 2004 Jul;6(7):420-4 [15274534.001]

[Cites] Trends Immunol. 2004 Aug;25(8):422-6 [15275641.001]

[Cites] Cancer Chemother Biol Response Modif. 2003;21:717-46 [15338771.001]

[Cites] Semin Cancer Biol. 2004 Dec;14(6):453-71 [15489139.001]

[Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]

[Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]

[Cites] EMBO J. 1989 Dec 20;8(13):4099-105 [2556261.001]

[Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]

[Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]

[Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]

[Cites] Viral Immunol. 2004;17(4):473-80 [15671745.001]

[Cites] Cleve Clin J Med. 2005 Jan;72(1):73-8 [15691060.001]

[Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65 [15718150.001]

[Cites] Curr Med Chem. 2005;12(3):357-74 [15723624.001]

[Cites] Expert Opin Emerg Drugs. 2005 Feb;10(1):5-19 [15757400.001]

[Cites] Annu Rev Pharmacol Toxicol. 2005;45:465-76 [15822185.001]

[Cites] J Virol. 2005 May;79(9):5705-12 [15827185.001]

[Cites] Am J Clin Pathol. 2005 Feb;123(2):222-8 [15842046.001]

[Cites] Anticancer Drugs. 2005 Jun;16(5):475-81 [15846112.001]

[Cites] Cell Cycle. 2005 Feb;4(2):290-6 [15655370.001]

[Cites] Mem Inst Oswaldo Cruz. 2005 Feb;100(1):1-12 [15867955.001]

[Cites] AIDS Rev. 2005 Jan-Mar;7(1):56-61 [15875661.001]

[Cites] Oncologist. 2005 Jun-Jul;10(6):412-26 [15967835.001]

[Cites] Science. 2005 Jul 1;309(5731):127-30 [15994556.001]

[Cites] J Antimicrob Chemother. 2005 Aug;56(2):277-81 [16006448.001]

[Cites] EMBO J. 2006 Apr 19;25(8):1635-45 [16601694.001]

[Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]

[Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]

[Cites] Curr Mol Med. 2006 May;6(3):291-308 [16712476.001]

[Cites] Front Biosci. 2006;11:2672-713 [16720343.001]

[Cites] Cancer Treat Rev. 2006 Oct;32(6):445-55 [16860939.001]

[Cites] Cancer Res. 2006 Oct 15;66(20):9870-7 [17047048.001]

[Cites] Mol Cell Biol. 2007 Apr;27(8):2910-8 [17296724.001]

[Cites] Adv Cancer Res. 2000;78:1-29 [10547667.001]

[Cites] Oncogene. 1999 Dec 13;18(53):7690-700 [10618709.001]

[Cites] Virology. 2000 Mar 1;268(1):178-91 [10683340.001]

[Cites] Semin Cancer Biol. 1999 Dec;9(6):387-95 [10712885.001]

[Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):717-45 [12852653.001]

[Cites] Anticancer Res. 2003 May-Jun;23(3A):2133-8 [12894587.001]

[Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]

[Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]

[Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]

[Cites] Ann Med. 2003;35(6):404-12 [14572164.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6 [14663138.001]

[Cites] AIDS Rev. 2003 Oct-Dec;5(4):222-9 [15012001.001]

[Cites] Oncogene. 2004 Mar 15;23(11):2107-15 [15021898.001]

[Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]

[Cites] Mol Cell Biol. 2004 Jun;24(12):5089-93 [15169876.001]

[Cites] Curr Protein Pept Sci. 2004 Jun;5(3):153-61 [15180520.001]

[Cites] Oncologist. 2005 Aug;10(7):528-38 [16079320.001]

[Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]

[Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67 [15979320.001]

[Cites] Antivir Ther. 2005;10(6):745-51 [16218174.001]

[Cites] Essays Biochem. 2005;41:139-56 [16250903.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18431-6 [16344472.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18562-6 [16352731.001]

[Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]

[Cites] Ann Pharm Fr. 2005 Sep;63(5):343-9 [16385784.001]

[Cites] Ann N Y Acad Sci. 2005 Nov;1056:328-43 [16387699.001]

[Cites] Annu Rev Med. 2006;57:33-47 [16409135.001]

[Cites] Expert Opin Investig Drugs. 2006 Feb;15(2):117-30 [16433592.001]

[Cites] Yonsei Med J. 2006 Feb 28;47(1):1-14 [16502480.001]

[Cites] Cancer Gene Ther. 2006 May;13(5):445-50 [16341140.001]

[Cites] Curr Med Chem. 2006;13(7):745-54 [16611064.001]

[Cites] Nihon Rinsho. 2006 Mar;64 Suppl 3:635-8 [16615550.001]

[Cites] Int J Oncol. 2000 May;16(5):853-70 [10762621.001]

[Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]

[Cites] Bioessays. 2000 May;22(5):442-51 [10797484.001]

[Cites] Clin Lab Med. 2000 Jun;20(2):383-406 [10863646.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]

[Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]

[Cites] Adv Pharmacol. 2000;49:479-514 [11013772.001]

[Cites] Mol Cell Biol. 2000 Nov;20(22):8526-35 [11046148.001]

[Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]

[Cites] Hum Cell. 1992 Mar;5(1):25-41 [1329931.001]

[Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]

[Cites] Princess Takamatsu Symp. 1991;22:239-48 [1668886.001]

[Cites] Int J Cancer. 1993 Sep 9;55(2):208-12 [8370617.001]

[Cites] Hosp Pract (1995). 1996 Sep 15;31(9):41-8, 53-5, 59-60 [8814120.001]

[Cites] Mol Med Today. 1997 Jun;3(6):246-53 [9211415.001]

[Cites] Semin Cancer Biol. 1996 Dec;7(6):317-26 [9284524.001]

[Cites] J Biol Chem. 1997 Nov 28;272(48):30135-40 [9374493.001]

[Cites] FEBS Lett. 1997 Dec 22;420(1):25-7 [9450543.001]

[Cites] J Biol Chem. 1998 Mar 13;273(11):6439-45 [9497376.001]

[Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]

[Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]

[Cites] Trends Microbiol. 1998 Jul;6(7):276-82 [9717216.001]

[Cites] Oncogene. 1998 Dec 10;17(23):2943-54 [9881696.001]

[Cites] Front Biosci. 1999 May 15;4:D468-75 [10331991.001]

(PMID = 18047745.001).

[ISSN] 1471-2091

[Journal-full-title] BMC biochemistry

[ISO-abbreviation] BMC Biochem.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ubiquitin

[Number-of-references] 119

[Other-IDs] NLM/ PMC2106372

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary mediastinal large B-cell lymphoma in HIV: report of two cases.

Primary mediastinal large B cell lymphoma (PMLBCL) is a subtype of diffuse large B cell lymphoma arising in the mediastinum with distinctive clinical and morphological features.

Though diffuse large B cell lymphoma is one of the most common non-Hodgkin lymphoma associated with AIDS, there are no data available regarding the association of HIV and PMLBCL.

We report here two cases of PMLBCL arising in AIDS patients.

One of the two patients, a 25-year-old woman who had localized disease and evidence of Epstein-Barr virus in lymphoma cells, did not respond to chemotherapy and died of disease progression 5 months after diagnosis.

The second patient, a 38-year-old male with disseminated disease, responded to therapy and is disease-free after 9 months of follow-up.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):44-54 [8465656.001]

[Cites] J Pathol. 1992 Aug;167(4):381-4 [1328576.001]

[Cites] Blood. 1991 Aug 1;78(3):780-8 [1713514.001]

[Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]

[Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]

[Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]

[Cites] Blood. 2007 Aug 1;110(3):972-8 [17400912.001]

[Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]

[Cites] Am J Med Sci. 2005 Mar;329(3):136-8 [15767818.001]

[Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):1135-48 [8880201.001]

[Cites] Br J Haematol. 1995 Jun;90(2):235-43 [7794745.001]

[Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]

(PMID = 19669223.001).

[ISSN] 1868-9256

[Journal-full-title] Journal of hematopathology

[ISO-abbreviation] J Hematop

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Other-IDs] NLM/ PMC2713493

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cutaneous malignancy and human immunodeficiency virus disease.

Certain skin cancers occur with increased frequency or altered course in patients infected with HIV.

Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV.

The incidence of HIV-associated Kapsosi's sarcoma has markedly decreased since the advent of HIV antiretroviral therapy.

Cutaneous T-cell lymphoma (CTCL) is rare in this population.

Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed.

LEARNING OBJECTIVE: At the completion of this learning activity, participants should be familiar with the unique epidemiology, clinical course, and management of cutaneous malignancy in patients infected with HIV.

[MeSH-major] HIV Infections / epidemiology. Skin Neoplasms / epidemiology

[MeSH-minor] Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16443048.001).

[ISSN] 1097-6787

[Journal-full-title] Journal of the American Academy of Dermatology

[ISO-abbreviation] J. Am. Acad. Dermatol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Retroviral Agents

[Number-of-references] 274

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

These EBV-miRNAs are functional because internalization of exosomes by MoDC results in a dose-dependent, miRNA-mediated repression of confirmed EBV target genes, including CXCL11/ITAC, an immunoregulatory gene down-regulated in primary EBV-associated lymphomas.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]

[Cites] Nat Cell Biol. 2009 Sep;11(9):1143-9 [19684575.001]

[Cites] J Exp Med. 2003 Dec 1;198(11):1653-63 [14657218.001]

[Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]

[Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]

[Cites] J Exp Med. 1996 Mar 1;183(3):1161-72 [8642258.001]

[Cites] Immunity. 1998 Sep;9(3):395-404 [9768759.001]

[Cites] Blood. 2004 Nov 15;104(10):3257-66 [15284116.001]

[Cites] J Immunol. 2005 Jun 1;174(11):6599-607 [15905498.001]

[Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]

[Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]

[Cites] Blood. 2007 Feb 1;109(3):1043-50 [17018863.001]

[Cites] Nat Cell Biol. 2007 Jun;9(6):654-9 [17486113.001]

[Cites] Science. 2007 Jul 20;317(5836):376-81 [17641203.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9 [17911266.001]

[Cites] J Virol. 2007 Dec;81(24):13771-82 [17942535.001]

[Cites] Nat Biotechnol. 2007 Dec;25(12):1457-67 [18026085.001]

[Cites] AIDS. 2007 Oct 18;21(16):2141-9 [18090040.001]

[Cites] Nat Rev Immunol. 2008 Feb;8(2):120-30 [18204468.001]

[Cites] J Immunol. 2008 Mar 1;180(5):3081-90 [18292531.001]

[Cites] Cancer Res. 2008 Mar 1;68(5):1436-42 [18316607.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 [18663219.001]

[Cites] PLoS One. 2008;3(11):e3694 [19002258.001]

[Cites] Virology. 2008 Dec 20;382(2):257-66 [18950829.001]

[Cites] Nat Cell Biol. 2008 Dec;10(12):1470-6 [19011622.001]

[Cites] Semin Cancer Biol. 2008 Dec;18(6):388-96 [19013244.001]

[Cites] J Cell Biol. 2008 Dec 29;183(7):1187-91 [19103810.001]

[Cites] Nature. 2009 Jan 22;457(7228):421-5 [19158788.001]

[Cites] J Virol. 2009 Mar;83(5):2357-67 [19091858.001]

[Cites] Cell. 2009 Feb 20;136(4):592-7 [19239880.001]

[Cites] Virology. 2009 Apr 10;386(2):387-97 [19217135.001]

[Cites] Nat Rev Immunol. 2009 Aug;9(8):581-93 [19498381.001]

[Cites] Genes Dev. 2009 Aug 15;23(16):1971-9 [19684116.001]

[Cites] Nat Cell Biol. 2009 Sep;11(9):1150-6 [19684574.001]

[Cites] J Biol Chem. 2003 Mar 28;278(13):10963-72 [12519789.001]

(PMID = 20304794.001).

[ISSN] 1091-6490

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R01 CA065883

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Viral

[Other-IDs] NLM/ PMC2851954

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Viruses are the accepted cause of many important cancers including cancers of the cervix and anogenital area, the liver, some lymphomas, head and neck cancers and indirectly human immunodeficiency virus associated cancers.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 24281093.001).

[ISSN] 2072-6694

[Journal-full-title] Cancers

[ISO-abbreviation] Cancers (Basel)

[Language] eng

[Publication-type] Journal Article

[Publication-country] Switzerland

[Other-IDs] NLM/ PMC3835103

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Neuropathology of HIV/AIDS with an overview of the Indian scene.

Neurological manifestations of HIV infection and AIDS are being recognized with a frequency that parallels the increasing number of AIDS cases.

Next to sub-Saharan Africa, India has the second largest burden of HIV related pathology, essentially caused by HIV-1 clade C in both the geographic locales, in contrast to USA and Europe.

But the true prevalence of HIV related neuroinfections and pathology is not available due to inadequate medical facilities, social stigma and ignorance that lead to underdiagnosis.

Inspite of heavy burden of HIV/AIDS, HIV associated neoplasia is infrequent, including primary CNS lymphomas.

HIV encephalitis and HIV associated dementia are considered infrequent, though systematic studies have just been initiated in various centres.

Till now the AIDS cases in India were drug naive but a new cohort of cases following initiation of HAART therapy as a national policy is soon emerging, altering the biology and evolution of HIV/AIDS in India.

Lacunae in the epidemiology, diagnosis and study of biology of HIV/AIDS are outlined for future research.

[MeSH-major] Central Nervous System Neoplasms / complications. HIV Infections / physiopathology. Nervous System Diseases / complications

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Neurologic Diseases.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15817957.001).

[ISSN] 0971-5916

[Journal-full-title] The Indian journal of medical research

[ISO-abbreviation] Indian J. Med. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review

[Publication-country] India

[Number-of-references] 153

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8.

Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma, composed of a monomorphic population of medium-sized B cells with a high proliferation rate and a consistent MYC translocation.

Epstein-Barr virus (EBV) has been associated with BL with different frequencies depending on the clinical variant.

Kaposi sarcoma-associated herpesvirus, or human herpesvirus 8 (HHV-8), infects a wide range of normal cells, having a well-established role in the pathogenesis of various neoplasms, including Kaposi sarcoma, primary effusion lymphoma, multicentric Castleman disease (MCD) and MCD-associated plasmablastic lymphoma.

In secondary immunodeficiencies, such as HIV-1 infection and organ transplantation, HHV-8 is considered an opportunistic pathogen linked to the development of lymphomas in patients with AIDS and HIV + patients.

We found no association of BL with HHV-8 in EBV + BL or in EBV-cases, including the HIV + BL group.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leukemia. 2005 Aug;19(8):1391-8 [15973450.001]

[Cites] J Exp Med. 2005 Aug 15;202(4):479-84 [16103407.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Br J Cancer. 2005 Oct 3;93(7):834-7 [16136049.001]

[Cites] J Clin Pathol. 2005 Oct;58(10):1039-45 [16189148.001]

[Cites] Am J Surg Pathol. 2006 Jan;30(1):123-7 [16330952.001]

[Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]

[Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]

[Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]

[Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]

[Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]

[Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]

[Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]

[Cites] Haematologica. 2005 Nov;90 Suppl:ECR35 [16266926.001]

[Cites] Hum Pathol. 1999 Oct;30(10):1269-70 [10534180.001]

[Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]

[Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]

[Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]

[Cites] Clin Infect Dis. 2002 Feb 15;34(4):559-60 [11797191.001]

[Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]

[Cites] Br J Haematol. 2003 Feb;120(3):471-7 [12580962.001]

[Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]

[Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]

[Cites] Acta Otolaryngol. 2004 Apr;124(3):318-23 [15141762.001]

[Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]

[Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]

[Cites] Blood. 1995 Mar 1;85(5):1396-403 [7858270.001]

[Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]

[Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]

[Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]

[Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]

[Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]

[Cites] Arch Dermatol. 1998 Jun;134(6):751 [9645650.001]

[Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]

[Cites] J Cutan Pathol. 2005 Jan;32(1):21-7 [15660651.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

[Cites] J Clin Pathol. 2005 Jun;58(6):626-8 [15917415.001]

(PMID = 18628086.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / CA121947-016821

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Other-IDs] NLM/ NIHMS125501; NLM/ PMC2718775

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas.

The role of p53 in primary effusion lymphoma (PEL) is complicated.

The latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus (KSHV) binds p53.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]

[Cites] J Virol. 2003 Jun;77(12):7093-100 [12768028.001]

[Cites] Cancer Cell. 2003 Nov;4(5):371-81 [14667504.001]

[Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]

[Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]

[Cites] Virology. 2004 Feb 20;319(2):225-36 [14980483.001]

[Cites] J Biol Chem. 2004 Apr 16;279(16):16822-31 [14742422.001]

[Cites] J Virol. 2004 Sep;78(18):10074-85 [15331740.001]

[Cites] J Virol. 2004 Oct;78(19):10336-47 [15367600.001]

[Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]

[Cites] J Virol. 2004 Oct;78(20):11121-9 [15452232.001]

[Cites] J Virol. 2004 Nov;78(22):12566-75 [15507644.001]

[Cites] Nature. 1979 Mar 15;278(5701):261-3 [218111.001]

[Cites] Cell. 1979 May;17(1):43-52 [222475.001]

[Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]

[Cites] Cell. 1983 Nov;35(1):79-87 [6313230.001]

[Cites] Nature. 1987 Oct 1-7;329(6138):456-8 [3309672.001]

[Cites] Nature. 1987 Oct 1-7;329(6138):458-60 [2821401.001]

[Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]

[Cites] J Virol. 1991 Oct;65(10):5417-24 [1895390.001]

[Cites] Genes Dev. 1991 Dec;5(12B):2375-85 [1752433.001]

[Cites] Virology. 1992 Mar;187(1):343-7 [1736539.001]

[Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]

[Cites] Genes Dev. 1992 Oct;6(10):1886-98 [1398068.001]

[Cites] Nature. 1993 Apr 29;362(6423):847-9 [8479522.001]

[Cites] Nat Genet. 1993 May;4(1):42-6 [8099841.001]

[Cites] Genes Dev. 1993 Jul;7(7A):1126-32 [8319905.001]

[Cites] FASEB J. 1993 Jul;7(10):951-6 [8344493.001]

[Cites] J Virol. 1994 May;68(5):2869-78 [8151757.001]

[Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4407-11 [7753819.001]

[Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]

[Cites] EMBO J. 1996 Oct 1;15(19):5349-57 [8895579.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]

[Cites] Science. 1996 Nov 8;274(5289):948-53 [8875929.001]

[Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]

[Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]

[Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]

[Cites] J Virol. 1999 Dec;73(12):9789-95 [10559289.001]

[Cites] J Clin Invest. 1997 Nov 15;100(10):2606-10 [9366576.001]

[Cites] Oncogene. 1998 Mar;16(11):1429-41 [9525742.001]

[Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]

[Cites] J Virol. 1998 Oct;72(10):8143-9 [9733855.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3077-80 [10077639.001]

[Cites] J Hum Virol. 1997 Nov-Dec;1(1):19-29 [10195227.001]

[Cites] FEBS Lett. 1999 Mar 19;447(1):5-9 [10218570.001]

[Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]

[Cites] J Virol. 1999 Jun;73(6):5149-55 [10233979.001]

[Cites] J Virol. 2004 Dec;78(24):14033-8 [15564510.001]

[Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]

[Cites] J Virol. 2005 Mar;79(6):3468-78 [15731241.001]

[Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]

[Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]

[Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]

[Cites] J Virol. 2005 Nov;79(21):13618-29 [16227282.001]

[Cites] J Virol. 2005 Nov;79(21):13829-36 [16227305.001]

[Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]

[Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]

[Cites] J Virol. 2006 Mar;80(5):2243-56 [16474132.001]

[Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]

[Cites] Cancer Res. 2006 Mar 15;66(6):3169-76 [16540668.001]

[Cites] Blood. 2006 May 15;107(10):4122-9 [16439677.001]

[Cites] J Virol. 2006 Jun;80(11):5273-82 [16699007.001]

[Cites] J Clin Invest. 2006 Jul;116(7):1963-73 [16794734.001]

[Cites] J Virol. 2006 Sep;80(18):9017-30 [16940514.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14554-9 [16983096.001]

[Cites] J Virol. 2006 Nov;80(21):10772-86 [16928766.001]

[Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]

[Cites] Virology. 2007 Jan 20;357(2):149-57 [16979209.001]

[Cites] J Virol. 2007 Feb;81(4):1912-22 [17121789.001]

[Cites] J Virol. 2007 Apr;81(8):4348-56 [17287261.001]

[Cites] J Clin Invest. 2007 Apr;117(4):1019-28 [17364023.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12365-70 [17640893.001]

[Cites] Curr Opin Oncol. 2007 Sep;19(5):452-7 [17762570.001]

[Cites] Blood. 2008 Oct 1;112(7):2886-95 [18633130.001]

[Cites] Blood. 2008 Nov 1;112(9):3827-34 [18682598.001]

[Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]

[Cites] J Gen Virol. 1999 Nov;80 ( Pt 11):2889-900 [10580050.001]

[Cites] J Exp Med. 1999 Dec 20;190(12):1857-68 [10601360.001]

[Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]

[Cites] Mol Cell Biol. 2000 Feb;20(3):1001-7 [10629057.001]

[Cites] J Biol Chem. 2000 Mar 24;275(12):8945-51 [10722742.001]

[Cites] Oncogene. 2000 Mar 9;19(11):1473-6 [10723139.001]

[Cites] J Virol. 2000 Sep;74(18):8532-40 [10954554.001]

[Cites] J Biol Chem. 2000 Sep 8;275(36):28039-44 [10827196.001]

[Cites] Nat Cell Biol. 2000 Sep;2(9):563-8 [10980695.001]

[Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]

[Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]

[Cites] J Gen Virol. 2000 Nov;81(Pt 11):2645-52 [11038375.001]

[Cites] J Virol. 2001 Jan;75(1):458-68 [11119614.001]

[Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]

[Cites] J Virol. 2001 Apr;75(7):3250-8 [11238851.001]

[Cites] J Biol Chem. 2001 Jun 22;276(25):22971-8 [11313352.001]

[Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]

[Cites] J Biol Chem. 2001 Aug 17;276(33):31016-22 [11425857.001]

[Cites] J Virol. 2001 Sep;75(18):8761-71 [11507221.001]

[Cites] J Virol. 2001 Oct;75(19):9446-57 [11533207.001]

[Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]

[Cites] J Gen Virol. 2002 Jan;83(Pt 1):179-88 [11752715.001]

[Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]

[Cites] J Biol Chem. 2002 Jul 26;277(30):27401-11 [12015325.001]

[Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]

[Cites] J Virol. 2002 Dec;76(24):12917-24 [12438617.001]

(PMID = 20130056.001).

[ISSN] 1098-5514

[Journal-full-title] Journal of virology

[ISO-abbreviation] J. Virol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / T32 CA009156; United States / NCI NIH HHS / CA / CA009156; United States / NCI NIH HHS / CA / CA109232-01; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NCI NIH HHS / CA / CA109232-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / latency-associated nuclear antigen

[Other-IDs] NLM/ PMC2849491